Prof Adam Waldman
MRC Institute of Genetics & Molecular Medicine CANCER RESEARCH UK Imaging
The overall theme of my research is development and validation of quantitative and molecular imaging biomarkers which reflect key features of genetics and metabolism in human glioma, for clinical stratification, therapeutic planning and drug development:
Experimental phase MRI and PET imaging studies of intermediary metabolism, validated against tissue metabolic markers from defined tumour regions; for more reliable tumour characterisation, and identification of potential therapeutic targets.
Translational multi-centre platform studies of early therapeutic response in GBM using quantitative diffusion imaging for improved endpoints in clinical trials and clinical decision-making.
Quantitative MRI for treatment stratification and planning in adult supratentorial low grade glioma.
Development of PET-MRI methodology and co-analysis for improved glioma characterization.
Integration of quantitative MRI and PET into surgical neuro-navigation systems, for improved targeting for biopsy and surgical resection.
Biomarkers in Adult Glioma
EVEN MORE SEMINARS
John Watkinson, MBBS, FRCS, DLO, MSc BUPA Cromwell Hospital
Consultant ENT Surgeon
Professor of Experimental Medicine
Rob Duncombe The Christie NHS Foundation Trust
Medicine Optimisation in Oncology. How to achieve best value.
Sanjay P Prabhu Boston Children’s Hospital & Harvard Medical School
Evolving role of machine learning in brain tumour imaging
Dr Shreerang Bhide Royal Marsden Hospital
Circulating HPV DNA in Locally advanced head and neck cancer.